{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T07:47:31Z","timestamp":1795160851553,"version":"4.10.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,12]]},"DOI":"10.7759\/cureus.13859","type":"journal-article","created":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T01:46:37Z","timestamp":1615599997000},"source":"Crossref","is-referenced-by-count":4,"title":["Hedgehog Pathway Inhibitors: Clinical Implications and Resistance in the Treatment of Basal Cell Carcinoma"],"prefix":"10.7759","author":[{"given":"Suzanne","family":"Habashy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Jafri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba O","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena E","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somtochi","family":"Udekwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey E","family":"Heindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22690","article-title":"Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond","volume":"56","author":"Bakshi A","year":"2017","unstructured":"Bakshi A, Chaudhary SC, Rana M, Elmets CA, Athar M. Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond. Mol Carcinog. 2017, 56:2543-2557. 10.1002\/mc.22690","journal-title":"Mol Carcinog"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial","volume":"86","author":"Basset-S\u00e9guin N","year":"2017","unstructured":"Basset-S\u00e9guin N, Hauschild A, Kunstfeld R, et al.. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017, 86:334-348. 10.1016\/j.ejca.2017.08.022","journal-title":"Eur J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/17-181","article-title":"Invasive basal cell carcinoma of the skin treated successfully with vismodegib: a case report","volume":"22","author":"Awad R","year":"2018","unstructured":"Awad R, Andrade JCB, Mousa H, Mahmoud F. Invasive basal cell carcinoma of the skin treated successfully with vismodegib: a case report. Perm J. 2018, 22:17-181. 10.7812\/TPP\/17-181","journal-title":"Perm J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0924","article-title":"A practical guide for the follow\u2010up of patients with advanced basal cell carcinoma during treatment with hedghehog pathway inhibitors","volume":"24","author":"Dessinioti C","year":"2019","unstructured":"Dessinioti C, Plaka M, Soura E, Mortaki D, Papaxoinis G, Gogas H, Stratigos AJ. A practical guide for the follow\u2010up of patients with advanced basal cell carcinoma during treatment with hedghehog pathway inhibitors. Oncologist. 2019, 24:755-764. 10.1634\/theoncologist.2018-0924","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58117-0","article-title":"Gene-related response of basal cell carcinoma to biologic treatment with vismodegib","volume":"10","author":"Sternfeld A","year":"2020","unstructured":"Sternfeld A, Rosenwasser-Weiss S, Ben-Yehuda G, et al.. Gene-related response of basal cell carcinoma to biologic treatment with vismodegib. Sci Rep. 2020, 10:1244. 10.1038\/s41598-020-58117-0","journal-title":"Sci Rep"},{"key":"ref6","article-title":"Dermatology","author":"Bolognia JL","year":"2017","unstructured":"Bolognia JL, Schaffer J, Cerroni L. Dermatology. Elsevier Team (ed): Elsevier, United Kingdom; 2017."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1588","article-title":"An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma resistant to vismodegib","volume":"22","author":"Danial C","year":"2016","unstructured":"Danial C, Sarin KY, Oro AE, Chang ALS. An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma resistant to vismodegib. Clin Cancer Res. 2016, 22:1325-1329. 10.1158\/1078-0432.CCR-15-1588","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70198-1","article-title":"Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial","volume":"16","author":"Basset-Segium N","year":"2015","unstructured":"Basset-Segium N, Hauschild A, Grob JJ, et al.. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015, 16:729-736. 10.1016\/S1470-2045(15)70198-1","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3286-5","article-title":"Long term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","volume":"17","author":"Sekulic A","year":"2017","unstructured":"Sekulic A, Migden MR, Basset-Sequin N, et al.. Long term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017, 17:332. 10.1186\/s12885-017-3286-5","journal-title":"BMC Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00371-1","article-title":"Low-dose vismodegib as maintenance therapy after locally advanced basal cell carcinoma complete remission: high efficacy with minimal toxicity","volume":"10","author":"Scalvenzi M","year":"2020","unstructured":"Scalvenzi M, Cappello M, Costa C, Fabbrocini G, Luciano M, Villani A. Low-dose vismodegib as maintenance therapy after locally advanced basal cell carcinoma complete remission: high efficacy with minimal toxicity. Dermatol Ther (Heidelb). 2020, 10:465-468. 10.1007\/s13555-020-00371-1","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4322\/acr.2019.116","article-title":"Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib","volume":"9","author":"Martins PC","year":"2019","unstructured":"Martins PC, Filipe RV, Barbosa R, Juliao I, Azevedo R, Riberio M, de Sousa A. Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib. Autops Case Rep. 2019, 9:2019116. 10.4322\/acr.2019.116","journal-title":"Autops Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00323-4","article-title":"Long-term efficacy of vismodegib after its withdrawal and patients' health related quality of life using the Dermatology Life Quality Index (DLQI)","volume":"9","author":"Vilani A","year":"2019","unstructured":"Vilani A, Megna M, Fabbrocini G, Cappello M, Luciano MA, Costa C, Scalvenzi M.. Long-term efficacy of vismodegib after its withdrawal and patients' health related quality of life using the Dermatology Life Quality Index (DLQI). Dermatol Ther (Heidelb). 2019, 9:719-724. 10.1007\/s13555-019-00323-4","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.09.003","article-title":"Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma","volume":"9","author":"Pricl S","year":"2015","unstructured":"Pricl S, Cortelazzi B, Col VD, et al.. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015, 9:389-397. 10.1016\/j.molonc.2014.09.003","journal-title":"Mol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.5473","article-title":"Effects of combined treatment with arsenic trioxide and itraconazole in pateints with refratory metastatic basal cell carcinoma","volume":"152","author":"Ally MS","year":"2016","unstructured":"Ally MS, Ransohoff K, Sarin K, et al.. Effects of combined treatment with arsenic trioxide and itraconazole in pateints with refratory metastatic basal cell carcinoma. JAMA Dermatol. 2016, 152:452-456. 10.1001\/jamadermatol.2015.5473","journal-title":"JAMA Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4451-1","article-title":"A computational study of hedgehog signaling involved in basal cell carcinoma reveals the potential and limitation of combination therapy","volume":"18","author":"Buetti-Dinh A","year":"2018","unstructured":"Buetti-Dinh A, Jensen R, Friedman R. A computational study of hedgehog signaling involved in basal cell carcinoma reveals the potential and limitation of combination therapy. BMC Cancer. 2018, 18:569. 10.1186\/s12885-018-4451-1","journal-title":"BMC Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2020-206448","article-title":"Clues to primary vismodegib resistance lie in histology and genetics","volume":"73","author":"Sun Q","year":"2020","unstructured":"Sun Q, Atzmony L,  Zaki T, Peng A, Sugarman J, Choate KA. Clues to primary vismodegib resistance lie in histology and genetics. J Clin Pathol. 2020, 73:678-680. 10.1136\/jclinpath-2020-206448","journal-title":"J Clin Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/51659-hedgehog-pathway-inhibitors-clinical-implications-and-resistance-in-the-treatment-of-basal-cell-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:25:16Z","timestamp":1707506716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/51659-hedgehog-pathway-inhibitors-clinical-implications-and-resistance-in-the-treatment-of-basal-cell-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.13859","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,12]]}}}